Patent ID: 8008003
Filing Date: 2011-08-30
Classification: C12Q

Abstract:
1. A method for predicting the likelihood that a human colon cancer patient will exhibit a clinically beneficial patient response to treatment with cetuximab, the method comprising: a) assaying a normalized level of a predictive RNA transcript in a sample comprising ErbB1-expressing colon cancer cells obtained from said patient, wherein the predictive RNA transcript is the transcript of laminin gamma 2 (LAMC2); b) analyzing the normalized level of the LAMC2 transcript; and c) predicting the likelihood of response of the patient to treatment with cetuximab by comparing the normalized level of the LAMC2 transcript to gene expression data obtained from reference samples derived from patients with colon cancer, wherein an increased normalized level of LAMC2 RNA transcript correlates with a decreased likelihood of response to treatment with cetuximab.